- Open Access
Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer
- Ming Shi†1,
- Dan Liu†2,
- Huijun Duan2Email author,
- Caili Han2,
- Bo Wei3,
- Lu Qian1,
- Changguo Chen1,
- Liang Guo1,
- Meiru Hu1,
- Ming Yu1,
- Lun Song1,
- Beifen Shen1 and
- Ning Guo1Email author
© Shi et al; licensee BioMed Central Ltd. 2010
- Received: 8 June 2010
- Accepted: 12 October 2010
- Published: 12 October 2010
Stress, anxiety and depression can cause complex physiological and neuroendocrine changes, resulting in increased level of stress related hormone catecholamine, which may constitute a primary mechanism by which physiological factors impact gene expression in tumors. In the present study, we investigated the effects of catecholamine stimulation on MMP-7 expression in gastric cancer cells and elucidated the molecular mechanisms of the up-regulation of MMP-7 level by catecholamine through an adrenergic signaling pathway.
Increased MMP-7 expression was identified at both mRNA and protein levels in the gastric cancer cells in response to isoproterenol stimulation. β2-AR antigonist effectively abrogated isoproterenol-induced MMP-7 expression. The activation of STAT3 and AP-1 was prominently induced by isoproterenol stimulation and AP-1 displayed a greater efficacy than STAT3 in isoproterenol-induced MMP-7 expression. Mutagenesis of three STAT3 binding sites in MMP-7 promoter failed to repress the transactivation of MMP-7 promoter and silencing STAT3 expression was not effective in preventing isoproterenol-induced MMP-7 expression. However, isoproterenol-induced MMP-7 promoter activities were completely disappeared when the AP-1 site was mutated. STAT3 and c-Jun could physically interact and bind to the AP-1 site, implicating that the interplay of both transcriptional factors on the AP-1 site is responsible for isoproterenol-stimulated MMP-7 expression in gastric cancer cells. The expression of MMP-7 in gastric cancer tissues was found to be at the site where β2-AR was overexpressed and the levels of MMP-7 and β2-AR were the highest in the metastatic locus of gastric cancer.
Up-regulation of MMP-7 expression through β2-AR-mediated signaling pathway is involved in invasion and metastasis of gastric cancer.
- Gastric Cancer
- Gastric Cancer Cell
- Gastric Cancer Cell Line
- Gastric Cancer Tissue
Gastric cancer is the second most common leading cause of cancer related death, with around 700 000 deaths each year [1, 2]. One of the important factors in the pathogenesis of gastric cancer is chronic infection with Helicobacter pylori. However, the majority of infected individuals do not develop malignancy and the outcome of the infection is dependent on host, environmental and other factors . There is growing evidence supporting the role of psychological stress in the gastric cancer onset and development . Several epidemiological studies have demonstrated that psychological or behavioral stress factors may accelerate the progression of gastric cancer [6, 7]. However, the precise mechanism by which psychological stress acts in gastric cancer progression is unclear.
Stress initiates a response of the hypothalamic-pituitary-adrenal axis (HPA), resulting in increased catecholamine level [8, 9]. Several studies have shown that the stimulation of catecholamine interferes with bio-behaviors of tumor cells directly, mainly through β2-adrenergic receptors (β2-AR)-mediated signaling pathway [10–14]. Recent observations pointing to a potential mechanism for the progression of ovarian, nasopharyngeal and pancreatic cancers indicate that catecholamine may modulate the expression of matrix metalloproteinase (MMP)-2 and MMP-9 by stroma and tumor cells [15–17]. It raises an interesting question that psychological stress may play a role in the development and progression of gastric cancer by modulating the expression of MMPs through β2-AR mediated signaling pathway.
Accumulated lines of evidence show that MMP-7 is involved in the invasion and metastases of gastric cancer [18–24]. MMP-7 is the smallest known member of MMP family and possesses the highest extracellular matrix (ECM)-degradative activity against a variety of ECM components, including elastin, gelatin, type IV collagen, fibronectin, vitronectin, laminin, entactin, aggrecan and proteoglycans, among the MMPs [25, 26]. It is also capable of triggering the activation of an MMP cascade . A unique feature of MMP-7 is its restricted expression predominantly in epithelial cells of glandular tissue including normal mammary, liver, pancreas, prostate and peribronchial glands .
It has been found that MMP-7 is overexpressed in the invasive cancers of digestive organs, such as oesophageal , gastric , pancreatic [31, 32], colorectal [33–35], liver  and other organs. The expression level of MMP-7 is significantly associated with the transformation of tumor cells, phenotypes of aggressive cancers and stage of tumor progression , especially in tumors of gastrointestinal tract. The overexpression of MMP-7 is frequently identified in premalignant gastric lesions and most gastric carcinomas [18–21, 24, 38]. A positive correlation of MMP-7 level with the tumor invasion of the gastric wall, lymph node metastasis, peritoneal dissemination and survival of gastric cancer patients has been documented in several studies . MMP-7 has been recognized as an important mediator of cancer progression and considered as an independent prognostic marker for primary gastric cancer. However, the possible molecular mechanisms of MMP-7 overexpression in gastric cancer are still largely unexplored.
In the present study, we investigated the effects of catecholamine stimulation on MMP-7 expression in gastric cancer cell lines and elucidated the molecular mechanisms of the up-regulation of MMP-7 level by catecholamine through an adrenergic signaling pathway.
Isoproterenol stimulation up-regulates the expression of MMP-7
Isoproterenol up-regulates MMP-7 promoter activity and activates STAT3 and AP-1
In our previous study [42, 43], we identified an AP-1 binding site at the position -67 to -61 and three STAT3 binding sites at the positions -137 to -122, -168 to -159 and -255 to -245 in MMP-7 promoter (Fig. 2A). We also demonstrated that AP-1 and STAT3 bound to AP-1 and one of the STAT3 (-137 to -122) sites, positively regulating MMP-7 transcription. A recent study showed that catecholamine has the potential to activate STAT3. To investigate whether catecholamine stimulates MMP-7 transcription via the activation of STAT3 and AP-1, we analyzed the phosphorylation of STAT3 and c-Jun. Fig. 2C showed that isoproterenol caused the phosphorylation of STAT3 after 30 min stimulation, reaching a peak at 2 h. Although the activation of c-Jun was slow, initiated at 60 min, a maximum phosphorylation was achieved at 2 h as well (Fig. 2D). It signified that isoproterenol stimulation produced a β2-AR-mediated signal that triggered the activation of STAT3 and AP-1.
STAT3 element in MMP-7 promoter is not required and STAT3 not sufficient for isoproterenol-induced MMP-7 expression
AP-1 plays a critical role in isoproterenol-induced MMP-7 expression
To confirm isoproterenol-induced MMP-7 expression is controlled by AP-1, we then examined whether the transactivation of MMP-7 promoter induced by isoproterenol could be inhibited by a dominant negative c-Jun mutant TAM67, which lacks the c-Jun 5'-transactivating domain but possesses a functional c-Jun leucine zipper and DNA-binding domain. After transient transfection with TAM67 into MGC-803 cells, isoproterenol-induced transactivation of MMP-7 promoter was analyzed by luciferase assays. As shown in Fig. 4C, the expression of the dominant negative c-Jun exhibited a conspicuous dampening impact on MMP-7 promoter activities. To further verify the critical role of AP-1, we tested whether blocking endogenously expressed c-Jun can inhibit the expression of MMP-7. The MGC-803/c-Jun-sh cells were established (Fig. 4D) and MMP-7 promoter activities analyzed by luciferase assays. The data in Fig. 4E showed that the activities of MMP-7 promoter were strikingly reduced by knock-down of c-Jun expression. Western blot analysis also demonstrated that isoprotereol-induced MMP-7 expression was markedly decreased in MGC-803/c-Jun-sh cells, whereas a substantially large amount of MMP-7 protein was detected in the parental cells after isoproterenol stimulation (Fig. 4F). Notably, the overexpression of exogenous c-Jun dramatically restored MMP-7 promoter activities in MGC-803/c-Jun-sh cells, but constitutively activated STAT3 mutant STAT3C only minimally activated MMP-7 promoter when c-Jun expression was silenced (Fig. 4G). These data proved that AP-1 dominated isoproterenol-induced MMP-7 expression.
c-Jun and STAT3 synergistically regulate MMP-7 expression in response to isoproterenol stimulation
Cooperation of Stat3 and c-Jun in regulating a variety of gene transcription has been reported. Our previous study demonstrates that the activation of MMP-9 promoter is dependent upon the interaction of Stat3 and AP-1 . As mentioned above, isoproterenol stimulation induced the activation of STAT3 and AP-1 simultaneously. We speculated that Stat3 and AP-1 may synergistically participate in the regulation of isoproterenol-stimulated MMP-7 expression. It has been indicated that AP-1 cooperates with STAT3 in interleukin 6-induced transactivation of the IL-6 response element in the absence of direct AP-1 DNA binding . It prompted us to test the possible cooperative binding of AP-1/STAT3 to the AP-1 site.
To further characterize the interaction of STAT3/c-Jun with the AP-1 site, we performed a DNA affinity precipitation assay. After MGC-803 cells were treated with isoproterenol for 2.5 h, the nuclear extract was prepared and its quality was assessed (Fig. 5C). The biotinylated oligonucleotides corresponding to -74 to -52 region of MMP-7 promoter were incubated with 200 μg of the nuclear extracts for the pull-down assays. The streptavidin coated magnetic beads were used to precipitate biotin-labeled double-stranded oligonucleotides and associated DNA binding proteins. The binding of the nuclear proteins to the biotinylated oligonucleotides was analyzed in the presence of one, five, or 15 fold amount of double-stranded oligonucleotide competitors containing AP-1 consensus sequences. Incubation of the nuclear proteins with the double-stranded oligonucleotides containing a mutated AP-1 site or non-specific double-stranded oligonucleotides was used as controls. The resulting DNA-protein complexes were resolved by SDS-PAGE, followed by Western blot with anti-c-Jun and anti-STAT3 antibodies. The association of both transcriptional factors with the oligonucleotides containing AP-1 consensus sequences could be clearly detected in the nuclear extracts from isoproterenol-stimulated cells, but not from unstimulated cells. Competition with fifteen fold amount of the competitors utterly abolished the formation of the biotinylated DNA/protein complexes (Fig. 5D). No binding of c-Jun and STAT3 to either the oligonucleotides containing a mutated AP-1 site or nonspecific oligonucleotides was detected (Fig. 5D). This experiment provides in vitro evidence to confirm that STAT3 and c-Jun, under catecholamine stimulation, can physically interact and bind to the AP-1 site to achieve transactivation of MMP-7 gene in gastric cancer cells.
We showed that isoproterenol-induced MMP-7 promoter activation was not disrupted by the mutagenesis of the core-sequences of all three STAT3 sites, suggesting that the STAT3 elements may not act in isoproterenol-induced MMP-7 gene transcription in gastric cancer cells. To further verify the role of AP-1 element, the plasmid pMMP-7mA was co-transfected into MGC-803 cells with either pCDNA3.1/c-Jun or STAT3C, respectively. Interestingly, the mutation of AP-1 binding site thoroughly blocked the activation of MMP-7 promoter in the transfected cells overexpressing either c-Jun or STAT3C (Fig. 5E and 5F), indicating that the AP-1 site is an important regulatory element and the synergistic regulation of isoproterenol-induced MMP-7 expression by STAT3 and AP-1 relies on this element.
β2-AR and MMP-7 were colocalized in gastric cancer tissues
The present study was based on the hypothesis that psychosocial stress may be a predisposing factor in gastric cancer. Stress, anxiety and depression can cause complex physiological and neuroendocrine changes that influence multiple systems, including the digestive system. The cancer patients often experience substantial emotional distress. The association of physiological stress with elevation of gastric acid secretion and stomachache has long been noticed [46, 47]. It has been reported that chronic stress can aggravate stomach ulcers. In a recent population-based survey enrolled 2014 subjects, stress was regarded as the most powerful risk factor in gastric cancer . The findings from experimental studies suggest that increased activity of the sympathetic nervous system may constitute a primary mechanism by which physiological factors impact gene expression in tumors . To date, most studies investigating the mechanisms connecting stress and cancer progression has been related to indirect effects through the immunosuppression . In several recent studies, stress related proteins and pathways were linked directly to the behavioral alteration of malignant cells [10–17]. However, there is a paucity of data delineating the molecular mechanisms involved.
In the present study, we identified increased MMP-7 expression in the gastric cancer cell lines in response to the stimulation of stress-related hormone catecholamine. It is estimated that the concentration of catecholamine could be over 100 times higher in the tumor microenvironment than in normal tissues and circulating plasma. MMP-7 is unique in its restricted expression in tumor cells, indicating that MMP-7 expression is in a tumor-associated fashion. We noticed that isoproterenol stimulation significantly up-regulated MMP-7 expression at both mRNA and protein levels in gastric cancer cells. β2-AR antigonist effectively abrogated isoproterenol-induced MMP-7 expression up-regulation, suggesting that β2-AR-mediated pathway is involved in the process.
MMP-7 expression is tightly controlled at the level of transcription. Our previous study demonstrated that heregulin-β-induced MMP-7 expression was regulated by HER2-mediated STAT3 and AP-1 activation in human breast cancer cell lines [42, 43]. We also identified the functional AP-1 and STAT3 binding sites in the first 350 bp of the transcription start site in human MMP-7 promoter [42, 43]. Another study indicated that FGF-2 could directly upregulate MMP-7 gene expression in human tumor cell lines and umbilical vein endothelial cells through AP-1 and STAT3 . Accumulating evidence strongly supports that STAT3 serves as a central regulatory node on which multiple oncogenic signaling pathways converge . Aberrant activation of STAT3 has been proved to play a critical role in gastric cancer development [52, 53]. A recent study and our data uncovered the association of catacholamine with STAT3 activation in ovarian and breast cancer cells [12, 13]. In the present study, we demonstrated that isoproterenol stimulation prominently induced the activation of STAT3 in gastric cancer cells, implicating that catecholamine may accelerate the malignant progression of gastric cancer. Our unpublished data also proved that isoproterenol stimulated the expression of MMP-2 and MMP-9 in gastric cancer cells mainly through activating STAT3. However, in this study, we found that AP-1 displayed a greater efficacy than STAT3 in isoproterenol-induced MMP-7 gene transcription and the STAT3 elements were non-functional, as silencing STAT3 expression was not effective in preventing isoproterenol-induced MMP-7 expression and mutagenesis of three STAT3 binding sites failed to repress the transactivation of MMP-7 promoter in response to isoproterenol induction. In contrast, the AP-1 site and c-Jun governed this process. Interestingly, STAT3 and c-Jun were found to bind to the single AP-1 site in MMP-7 promoter simultaneously, implicating that the interplay of both transcriptional factors at one binding site is responsible for isoproterenol-stimulated MMP-7 expression in gastric cancer cells. We have demonstrated that STAT3 and AP-1 are important transcriptional regulators of MMP-7 and MMP-9 in human breast cancer cells previously and STAT3 and AP-1 exert transcriptional regulation functions by binding to their respective elements [42–44]. Given the results of these data, catecholamine-induced MMP-7 expression may be primarily in a cell type specific manner.
Several lines of evidence indicate that the expression of MMP-7 is associated with advanced clinicopathological stages and unfavorable prognosis in gastric cancer [18–24, 38, 54]. Recent studies showed that MMP-7 expression was selectively up-regulated by pathogenic strains of Helicobacter pylori in Helicobacter pylori gastritis , which is considered as the initial stage in the progression to gastric carcinoma. MMP-7 is also identified as a target of gastrin in hypergastrinemia that is associated with gastric cancer . These data suggest that MMP-7 is an important mediator in gastric cancer development. MMP-7 affects the gastric microenvironment by degrading ECM components. It also plays a key role in the activation, degradation, release and shedding of cell-surface molecules, such as pro-heparin-binding epidermal growth factor, Fas ligand, a stimulator of the death receptor FAS, cell adhesion molecule E-cadherin and insulin-like growth factor binding protein, thus stimulating cellular proliferation, inhibiting apoptosis and promoting tissue invasion and metastasis . We noticed that the overexpression of MMP-7 emerged at the region where β2-AR was expressed highly and the level of MMP-7 and β2-AR is the highest in the metastatic locus of gastric cancer, suggesting a direct role of β2-AR-mediated MMP-7 expression in the invasion and metastasis of gastric cancer, and also implying an important effect of neuroendocrine "macroenvironment" on the gastric tumor microenvironment.
The main findings of this study strongly support the hypothesis that up-regulation of MMP-7 expression through β2-AR-mediated signaling pathway is involved in invasion and metastasis of gastric cancer. β2-AR may serve as a target of therapeutic intervention. An understanding of how MMP-7 gene is up-regulated under stress will help to elucidate the mechanisms of MMP-7 overexpression in gastric cancer, especially at an early stage. Further identification of the down-stream effector molecules of β2-AR cascades will not only provide a more definite knowledge of the signaling network in response to catecholamine stimulation, but also close an important gap linking psychosocial stress and the cellular consequences in gastric cancer.
Cell culture and treatment
Human gastric cancer cell lines HGC-27 and MGC-803 (the American Type Culture Collection) were incubated in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) at 37°C in a humidified atmosphere of 5% CO2. For the treatment with β-AR agonists, the cells were incubated overnight in serum-free medium supplemented with 0.1% BSA, 10 mM HEPES (pH 7.4) prior to stimulation. Then HGC-27 cells were treated with 0, 1, or 2 μM isoproterenol (Sigma) and MGC-803 cells 1, 5, or 10 μM isoproterenol for indicated time points. For β-AR antagonist treatment, the cells were first treated with 10 μM propranolol (TOCRIS) or 1 μM ICI-118,551 (TOCRIS) for 1 h before AR agonist stimulation.
The primers used
5' - GTTATTGGCAGGAAGCACAC - 3'
Transfection and luciferase assays
Cells were co-transfected with pMMP-7 or pMMP-7mS or pMMP-7mA and pRL-TK reporter plasmid containing the Renilla luciferase reporter gene using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. After transfection for 48 h, the cells were incubated in serum-free medium for an additional 24 h and then stimulated with 10 μM isoproterenol for indicated time points. For luciferase assays, cells were lysed in lysis buffer (Promega). Firefly and Renilla luciferase activities were measured with a dual luciferase assay kit (Promega) according to the manufacturer's instructions. All transfections were carried out in triplicate and repeated at least three times.
The whole cell lysates were prepared, separated by SDS-PAGE and transferred to PVDF membranes. After blocking, blots were probed with the appropriate primary antibodies overnight at 4°C. The antibodies used include anti-β2-AR rabbit polyclonal antibody (Santa Cruz Biotechnology Inc.), anti-MMP-7 mouse monoclonal antibody (Santa Cruz Biotechnology Inc.), anti-STAT3 rabbit polyclonal antibody (Cell Signaling Technology Inc.), anti-phosphor-STAT3 (Tyr705) rabbit polyclonal antibody (Cell Signaling Technology Inc.), anti-phosphor-c-Jun (Ser73) rabbit polyclonal antibody (Cell Signaling Technology Inc.), anti-β2-AR rabbit polyclonal antibody (Santa Cruz Biotechnology Inc.), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) rabbit monoclonal antibody (Cell Signaling Technology Inc.). The blots were then washed and incubated with horseradish peroxidase-conjugated secondary antibodies. Bands were detected by enhanced chemiluminesence (Pierce).
Conventional and real-time RT-PCR
For the examination of MMP-7 transcription induced by catecholamine, HGC-27 and MGC-803 cells were treated with 2 or 10 μM of isoproterenol for 12 h. Then, total RNA was isolated from HGC-27 and MGC-803 cells using TRIzol reagent (Invitrogen) following the manufacturer's instructions and quantified by spectrophotometry. cDNA was synthesized by reverse transcription kit (BioTeke) in accordance with the manufacturer's instructions and amplified by PCR with the specific primers P10 and P11 (Table 1) to screen the mRNA expression of MMP-7. The PCR products were electrophoresed on 1.0% agarose gel. Amplification of β-actin gene using the specific primers P12 and P13 (Table 1) was used as an internal control. Real-time PCR was performed using SYBR Green Supermix (TransGen Biotech) on Real-Time PCR Detection System (Eppendorf) as recommended by the manufacturer. The results were analyzed using the comparative threshold cycle method with β-actin as an internal control.
Paraffin-embedded tissues were cut (~5 μm). The sections were dewaxed in xylene, and gradually hydrated in a decreasing ethanol series ending in distilled water. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide in distilled water and then washed in phosphate-buffered saline (PBS). After antigen retrieval, the sections were incubated with anti-MMP-7 (Santa Cruz Biotechnology Inc.) and anti-β2-AR (Abcam) rabbit polyclonal antibodies. Following washing with PBS, the sections were subsequently incubated with horseradish peroxidase-conjugated anti-rabbit antibody (Gene Tech Biotechnology Co.). The color was developed by incubation with 3, 3'-diaminobenzidine solution. The sections were then counterstained with hematoxylin, dehydrated, and mounted. Omission of the primary antibody and substitution by non-specific rabbit IgG at the same concentration were used as negative controls.
Chromatin immunoprecipitation (ChIP)
MGC-803 cells were treated with 10 μM of isoproterenol for 0, 2.5 and 4 h under serum-free conditions after overnight starvation. The chromatin DNA of the cells was prepared and ChIP assay performed by using the SimpleChIPTM Enzymatic Chromatin IP Kit (Cell Signaling Technology Inc.) following the protocol supplied by the manufacturer. STAT3, c-Jun, and DNA complexes were precipitated either by anti-STAT3 antibody and anti-c-Jun antibody or by rabbit IgG as the negative control. Precipitated DNA was amplified by PCR with the primers P14 and P15 (Table 1) flanking AP-1 binding site (-67 to -61) in MMP-7 promoter. Final products were resolved on a 1% agarose gel.
Preparation of nuclear extracts and oligonucleotide pull-down assays
The 5'-biotinylated double-stranded oligonucleotides (5'-ACTCAAATGAGTCACCTATTTCC-3' and 5'-GGAAATAGGTGACTCATTTGAGT-3') corresponding to the positions -74 to -52 of MMP-7 promoter harboring AP-1 motif were synthesized by Invitrogen Biotechnology. The same double-stranded sequences that are not biotinylated were used as the competitors. The biotinylated oligonucleotides containing the mutated AP-1 binding site (5'-ACTCAAACGAGTGACCTATTTCC-3' and 5'-GGAAATAGGTCACTCGTTTGAGT-3'), in which conserved nucleotides of AP-1 consensus sequence were replaced, and the biotinylated oligonucleotides (5'-ACCAATGCAGCCCTACCTGTAGC-3' and 5'-GCTACAGGTAGGGCTGCATTGGT-3') corresponding to the positions -908 to -885 of MMP-7 promoter lacking the AP-1 binding site were also synthesized. MGC-803 cells were treated with 10 μM of isoproterenol for 0 or 2.5 h under serum-free conditions after overnight starvation. The nuclear extracts were prepared by using a Nuclear-Cytosol Extraction Kit (Applygen Technologies) according to the manufacturer's instructions. 200 μg of the nuclear extracts was incubated at 4°C for 4 h with each pair of the oligonucleotides previously coupled to Dynabeads M-280 (Invitrogen). The protein/DNA complexes were separated with a Dynal magnet, denatured in SDS sample buffer and subjected to SDS-PAGE. STAT3 and c-Jun were detected by Western blot with anti-STAT3 and anti-cJun antibodies.
All clinical tissue samples were obtained from General Hospital of PLA with the informed consent of patients and with approval for experiments from General Hospital of PLA. The peri-cancerous, cancerous and peritoneal metastatic tissues samples were obtained from a patient (male, 62 years old) diagnosed as advanced gastric cancer during radical subtotal gastrectomy.
We are very grateful to Drs. Bromber and Darnell for providing STAT3 dominant negative construct. This work is supported by National Basic Research Program of China (973 Program, No. 2006CB504305 and 2010CB911904), National High-Tech Research and Development Plan (863 Program, No. 2006AA02A245), National Key Technologies R&D Program for New Drugs (2009ZX09301-002 and 2009ZX09103-619), Grand Science and Technology Special programmes concerning prevention and treatment of infectious diseases (2008ZX10004-015) and National Natural Science Foundation of China (No. 30771981, 30901766, 30800582 and 30972690).
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74View ArticlePubMedGoogle Scholar
- Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL: Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009, 27: 812-826. 10.1200/JCO.2008.21.2134PubMed CentralView ArticlePubMedGoogle Scholar
- Polk DB, Peek RM: Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 10: 403-414.Google Scholar
- Smith MG, Hold GL, Tahara E, El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006, 12: 2979-2990.PubMed CentralPubMedGoogle Scholar
- Audier AG: Determination of a constitutional neuroendocrine factor probably influencing tumor development in man: prophylactic and therapeutic aspects. Cancer Detect Prev. 1988, 11: 203-208.PubMedGoogle Scholar
- Watabe K, Nishi M, Miyake H, Hirata K: Lifestyle and gastric cancer: a case-control study. Oncol Rep. 1998, 5: 1191-1194.PubMedGoogle Scholar
- Jansson C, Johansson AL, Jeding K, Dickman PW, Nyren O, Lagergren J: Psychosocial working conditions and the risk of esophageal and gastric cardia cancers. Eur J Epidemiol. 2004, 19: 631-641. 10.1023/B:EJEP.0000036806.51918.40View ArticlePubMedGoogle Scholar
- Glaser R, Kiecolt-Glaser JK: Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005, 5: 243-251. 10.1038/nri1571View ArticlePubMedGoogle Scholar
- Charmandari E, Tsigos C, Chrousos G: Endocrinology of the stress response. Annu Rev Physiol. 2005, 67: 259-284. 10.1146/annurev.physiol.67.040403.120816View ArticlePubMedGoogle Scholar
- Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK: Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010, 120: 1515-1523. 10.1172/JCI40802PubMed CentralView ArticlePubMedGoogle Scholar
- Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006, 12: 939-944. 10.1038/nm1447View ArticlePubMedGoogle Scholar
- Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK: Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007, 67: 10389-10396. 10.1158/0008-5472.CAN-07-0858View ArticlePubMedGoogle Scholar
- Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, Zhang H, Yong Z, Gong Z, Song L, Yu M, Hu M, Xia Q, Shen B, Guo N: The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2010: 17-Google Scholar
- Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK: Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007, 282: 29919-29926. 10.1074/jbc.M611539200View ArticlePubMedGoogle Scholar
- Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole SW, Lubaroff DM, Sood AK: Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008, 14: 6839-6846. 10.1158/1078-0432.CCR-08-0230PubMed CentralView ArticlePubMedGoogle Scholar
- Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R: Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006, 66: 10357-10364. 10.1158/0008-5472.CAN-06-2496View ArticlePubMedGoogle Scholar
- Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D, Zhang M: Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 2009, 22: 825-830.PubMedGoogle Scholar
- Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T: Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 1996, 39: 444-448. 10.1136/gut.39.3.444PubMed CentralView ArticlePubMedGoogle Scholar
- Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T, Kinoshita K, Endo Y, Sugiyama K, Sasaki T: Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res. 2001, 7: 1647-1653.PubMedGoogle Scholar
- Wroblewski LE, Noble PJ, Pagliocca A, Pritchard DM, Hart CA, Campbell F, Dodson AR, Dockray GJ, Varro A: Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci. 2003, 116: 3017-3026. 10.1242/jcs.00518View ArticlePubMedGoogle Scholar
- Bebb JR, Letley DP, Thomas RJ, Aviles F, Collins HM, Watson SA, Hand NM, Zaitoun A, Atherton JC: Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner. Gut. 2003, 52: 1408-1413. 10.1136/gut.52.10.1408PubMed CentralView ArticlePubMedGoogle Scholar
- Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K: Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis. 2004, 25: 325-332. 10.1093/carcin/bgh011View ArticlePubMedGoogle Scholar
- Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW: Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006, 95: 744-751. 10.1038/sj.bjc.6603307PubMed CentralView ArticlePubMedGoogle Scholar
- Ogden SR, Wroblewski LE, Weydig C, Romero-Gallo J, O'Brien DP, Israel DA, Krishna US, Fingleton B, Reynolds AB, Wessler S, Peek RM: p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7. Mol Biol Cell. 2008, 19: 4110-4121. 10.1091/mbc.E08-03-0283PubMed CentralView ArticlePubMedGoogle Scholar
- Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463PubMed CentralView ArticlePubMedGoogle Scholar
- Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745View ArticlePubMedGoogle Scholar
- von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB: Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem J. 1998, 331 (Pt 3): 965-972.PubMed CentralView ArticlePubMedGoogle Scholar
- Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMedGoogle Scholar
- Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res. 1999, 59: 3313-3316.PubMedGoogle Scholar
- Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T, Kuwano H: Clinical significance of mucin phenotype, beta-catenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma. Br J Surg. 2005, 92: 454-462. 10.1002/bjs.4868View ArticlePubMedGoogle Scholar
- Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol. 2001, 19: 1118-1127.PubMedGoogle Scholar
- Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res. 2004, 10: 2832-2845. 10.1158/1078-0432.CCR-1157-03View ArticlePubMedGoogle Scholar
- Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999, 45: 252-258. 10.1136/gut.45.2.252PubMed CentralView ArticlePubMedGoogle Scholar
- Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T, Imai K: Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer. 2001, 95: 290-294. 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-IView ArticlePubMedGoogle Scholar
- Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K: Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol. 2003, 199: 176-184. 10.1002/path.1277View ArticlePubMedGoogle Scholar
- Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, Imai K: Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology. 1997, 112: 1290-1296. 10.1016/S0016-5085(97)70143-4View ArticlePubMedGoogle Scholar
- Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006, 231: 20-27.Google Scholar
- Varro A, Kenny S, Hemers E, McCaig C, Przemeck S, Wang TC, Bodger K, Pritchard DM: Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G1133-1140. 10.1152/ajpgi.00526.2006View ArticlePubMedGoogle Scholar
- Speidl WS, Toller WG, Kaun C, Weiss TW, Pfaffenberger S, Kastl SP, Furnkranz A, Maurer G, Huber K, Metzler H, Wojta J: Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. Faseb J. 2004, 18: 603-605.PubMedGoogle Scholar
- Schmidt C, Kraft K: Beta-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur J Med Res. 1996, 1: 528-532.PubMedGoogle Scholar
- Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, Mayerhofer A, Guimaraes MA, Rosa ESAA, Ramirez VD: Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. Microsc Res Tech. 2002, 59: 495-502. 10.1002/jemt.10229View ArticlePubMedGoogle Scholar
- Yuan G, Qian L, Shi M, Lu F, Li D, Hu M, Yu M, Shen B, Guo N: HER2-dependent MMP-7 expression is mediated by activated STAT3. Cell Signal. 2008, 20: 1284-1291. 10.1016/j.cellsig.2008.02.017View ArticlePubMedGoogle Scholar
- Yuan G, Qian L, Song L, Shi M, Li D, Yu M, Hu M, Shen B, Guo N: Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells. Mol Cell Biochem. 2008, 318: 73-79. 10.1007/s11010-008-9858-6View ArticlePubMedGoogle Scholar
- Song Y, Qian L, Song S, Chen L, Zhang Y, Yuan G, Zhang H, Xia Q, Hu M, Yu M, Shi M, Jiang Z, Guo N: Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol Immunol. 2008, 45: 137-143. 10.1016/j.molimm.2007.04.031View ArticlePubMedGoogle Scholar
- Schuringa JJ, Timmer H, Luttickhuizen D, Vellenga E, Kruijer W: c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). Cytokine. 2001, 14: 78-87. 10.1006/cyto.2001.0856View ArticlePubMedGoogle Scholar
- Lehrer S: Life change and gastric cancer. Psychosom Med. 1980, 42: 499-502.View ArticlePubMedGoogle Scholar
- Verhaak PF: Somatic disease and psychological disorder. J Psychosom Res. 1997, 42: 261-273. 10.1016/S0022-3999(96)00325-XView ArticlePubMedGoogle Scholar
- Oh DY, Choi KS, Shin HR, Bang YJ: Public awareness of gastric cancer risk factors and disease screening in a high risk region: a population-based study. Cancer Res Treat. 2009, 41: 59-66. 10.4143/crt.2009.41.2.59PubMed CentralView ArticlePubMedGoogle Scholar
- Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK: The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006, 6: 240-248. 10.1038/nrc1820PubMed CentralView ArticlePubMedGoogle Scholar
- Holnthoner W, Kerenyi M, Groger M, Kratochvill F, Petzelbauer P: Regulation of matrilysin expression in endothelium by fibroblast growth factor-2. Biochem Biophys Res Commun. 2006, 342: 725-733. 10.1016/j.bbrc.2006.02.011View ArticlePubMedGoogle Scholar
- Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809. 10.1038/nrc2734View ArticlePubMedGoogle Scholar
- Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS: STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology. 2006, 131: 1073-1085. 10.1053/j.gastro.2006.07.018View ArticlePubMedGoogle Scholar
- Denson LA: Adding fuel to the fire: STAT3 priming of gastric tumorigenesis. Gastroenterology. 2006, 131: 1342-1344. 10.1053/j.gastro.2006.08.049View ArticlePubMedGoogle Scholar
- Chen JQ, Zhan WH, He YL, Peng JS, Wang JP, Cai SR, Ma JP: Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol. 2004, 10: 776-782.PubMedGoogle Scholar
- Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M, Shen B, Guo N: Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer. 2007, 7: 145- 10.1186/1471-2407-7-145PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.